Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Epithelial Ovarian Cancer: A Single-arm, Multi-center, Phase II Clinical Study

NCT05310344 is registered in ClinicalTrials.gov with Lei Li as lead sponsor.

NCT NCT05310344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05310344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Epithelial Ovarian Cancer: A Single-arm, Multi-center, Phase II Clinical Study
Lead sponsor
Lei Li
Phase
Phase 2
Overall status
Unknown status
Start date
March 27, 2022
Completion date
March 27, 2024
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse events, albumin-bound paclitaxel, bevacizumab, ovarian carcinoma, platinum-resistant ovarian cancer, recurrent ovarian carcinoma, survival outcomes